Accuray Merger Gets Shareholder OK - Analyst Blog
10 6월 2011 - 9:15PM
Zacks
Leading radiosurgery systems maker
Accuray Inc.’s (ARAY) impending acquisition of its
rival TomoTherapy (TOMO) has been approved by the
latter’s shareholders. The California-based company landed a cash
and stock deal (worth $277 million), in March 2011, to buy
Wisconsin-based radiation system maker TomoTherapy. The transaction
was cleared by the Boards of both companies.
Shareholders holding 79% of
TomoTherapy’s outstanding shares voted in favor of the deal. The
companies now expect the transaction to consummate within 1-2
business days, assuming the attainment of the customary closing
conditions.
Per the deal terms, Accuray is
acquiring TomoTherapy for $4.80 a share in cash and stock.
Shareholders of TomoTherapy will receive $3.15 in cash and 0.1648
shares of Accuray for each share they hold.
TomoTherapy, with annual sales of
$195 million, markets advanced radiation therapies for treating
multiple cancer types. Its solutions include the Hi-Art system,
which is designed for continuous delivery of radiation from all
angles around a patient. It targets tumors more precisely than
conventional radiation therapies while leaving surrounding healthy
tissues unharmed.
The deal marks the union of
TomoTherapy’s best-in-class radiation therapies with Accuray’s
popular radiosurgery systems to create a leading player in the
radiation oncology space. The combined entity will offer
state-of-the-art therapies, ranging from high-precision
radiosurgery to image-guided intensity-modulated radiation therapy,
for treating cancer and other diseases. The integrated company with
combined sales of more than $400 million will have a significant
global presence.
The acquisition will offer a major
boost to Accuray’s sales and will reinforce its foothold in the
radiation oncology space. The company expects the transaction to be
accretive to its earnings in the fiscal year beginning July 1, 2012
and will offer opportunities for cost synergies through increased
operating efficiencies, complementary patient base and overhead
reductions.
Accuray is a global leader in the
field of radiosurgery and provides a non-surgical treatment option
for patients diagnosed with cancer. Its CyberKnife robotic
radiosurgery systems continue to gain significant traction in the
global medical communities, thereby boosting sales. To date, more
than 100,000 people have been treated with CyberKnife globally.
Accuray is expected to benefit from
the gradual recovery in hospital capital equipment spending.
However, the company remains susceptible to reimbursement
uncertainties surrounding its products and its CyberKnife system
faces stiff challenges from
competitive product offerings of Varian Medical
(VAR). Currently, we are Neutral on Accuray.
ACCURAY INC (ARAY): Free Stock Analysis Report
TOMOTHERAPY INC (TOMO): Free Stock Analysis Report
VARIAN MEDICAL (VAR): Free Stock Analysis Report
Zacks Investment Research
Tom Online (NASDAQ:TOMO)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Tom Online (NASDAQ:TOMO)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024